Louisiana judge pauses challenge to FDA mail-order mifepristone rule, leaving access unchanged for now
The facts
- On Tuesday, U.S. District Judge David Joseph in Louisiana declined to immediately block the FDA rule allowing mifepristone to be dispensed by mail, leaving current access in place for now.
- Judge Joseph put Louisiana's lawsuit on hold while the FDA conducts a review of mifepristone's safety and the challenged rule.
- Louisiana had asked the court to pause or block the 2023 FDA rule that allows mifepristone to be dispensed through the mail while the case moved forward.
- The challenged FDA policy dates to 2023 and permits certified pharmacies or providers to dispense mifepristone by mail across state lines.
- Joseph said the case should not proceed until the FDA decides whether it will repeal or revise the 2023 regulation after its review.
- The judge indicated the pause is temporary rather than indefinite and said Louisiana could renew its request later.
Context
What did the judge actually decide?
He denied Louisiana's request to immediately stop the FDA's mail-dispensing rule for mifepristone and instead paused the case while the FDA completes its review, meaning the current rules stay in effect for now Reuters,U.S. News & World R…,FOX 5 Atlanta.
What rule is being challenged?
The lawsuit targets the FDA's 2023 rule that allows mifepristone to be dispensed through the mail, including through certified pharmacies, rather than only through in-person dispensing Aol,Reuters,U.S. News & World R….
What happens next?
The FDA is expected to complete its review before the case resumes, and the judge said Louisiana may renew its request to block the rule later if the dispute returns to court U.S. News & World R…,U.S. News & World R…,Boston Globe.
The receipts — 28 sources
Wire services (3)
Other coverage (25)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.